Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Daxor Corporation
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
November 17, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
November 15, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Daxor Corporation Announces Launch of Proposed Underwritten Public Offering
November 14, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs
November 10, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
November 03, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
October 31, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
October 05, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
October 04, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
October 04, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
October 03, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care
October 03, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures
October 03, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
July 27, 2022
From
Daxor Corporation
Via
GlobeNewswire
Tickers
DXR
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.